The Billionaire Biotech Boom: A Double Edged Sword in the Fight Against Cancer The recent surge in Moderna's stock price has catapulted co founder Robert Langer back into billionaire territory.
This development raises questions about the true cost of innovation in the biotech industry, particularly when it comes to cancer treatment.
Moderna's meteoric rise is a testament to its innovative approach, which has attracted significant investment and reaped handsome rewards for its founders.